Pro-Dex Inc

Pro-Dex Inc (PDEX) Stock Analysis

$62.555

-2.221 (-3.55%)At close

Loading chart…
High
64.890
Open
64.890
VWAP
63.21
Vol
56.66K
Mkt Cap
64.62M
Low
62.170
Amount
3.58M
EV/EBITDA, TTM
15.67

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. The Company has patented adoptive torque-limiting software and sealing solutions, which appeal to its customers, primarily medical device distributors. It also manufactures and sells rotary air motors to a range of industries. The Company’s medical device products utilize designs developed by it primarily under development and supply agreements and are machined in its Irvine, California facility, and assembled in its Tustin, California facility, as are its rotary air motors. Its medical device products are sold primarily to original equipment manufacturers and its air motors are sold primarily to a range of distributors and end users. It manufactures machined sub-assemblies and also produces parts and assemblies for aerospace and defense systems.

AI analysis of Pro-Dex Inc (PDEX)

hold

Pro-Dex Inc is currently not a strong buy due to its recent price decline and low RSI, but it shows potential for recovery in the long term. The current price is $62.55, with a 5-day change of -4.74%, indicating short-term weakness. However, the year-to-date change of +65.84% suggests strong long-term performance. The forward P/E ratio of 22.83 indicates that the stock may be overvalued at this price point, and the RSI of 30.09 suggests it is oversold, which could lead to a rebound. The main risk is the recent decline in revenue growth, with Q2 revenue at $18.66 million, which is lower than expected, impacting investor sentiment.

Analyst Ratings (1)

Buy
1 Buy
0 Hold
0 Sell
Current: 62.56
Low
Average
High

Ascendiant Capital

2024-11-11

Price Target

$52

Strong Buy

Ascendiant Capital

2024-09-09

Price Target

$30

Strong Buy

Valuation Metrics

The current forward P/E ratio for Pro-Dex Inc (PDEX) is 22.83, compared to its 5-year average forward P/E of 17.45.

Forward P/E

Fair
5Y Average P/E
17.45
Current P/E
22.83
Overvalued
23.50
Undervalued
11.40

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
10.44
Current EV/EBITDA
15.67
Overvalued
13.45
Undervalued
7.43

Forward P/S

Overvalued
5Y Average P/S
1.70
Current P/S
2.56
Overvalued
2.19
Undervalued
1.21

Alphio AI Price Scenarios for PDEX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PDEX

$55.23

Scenario price

B

Base

Base · 50%PDEX

$51.89

Scenario price

B

Bear

Bear · 25%PDEX

$51.20

Scenario price

PDEX FAQ — answered by Alphio AI

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. The Company has patented adoptive torque-limiting software and sealing solutions, which appeal to its customers, primarily medical device distributors. It also manufactures and sells rotary air motors to a range of industries. The Company’s medical device products utilize designs developed by it primarily under development and supply agreements and are machined in its Irvine, California facility, and assembled in its Tustin, California facility, as are its rotary air motors. Its medical device products are sold primarily to original equipment manufacturers and its air motors are sold primarily to a range of distributors and end users. It manufactures machined sub-assemblies and also produces parts and assemblies for aerospace and defense systems. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Pro-Dex Inc is currently not a strong buy due to its recent price decline and low RSI, but it shows potential for recovery in the long term. The current price is $62.55, with a 5-day change of -4.74%, indicating short-term weakness. However, the year-to-date change of +65.84% suggests strong long-term performance. The forward P/E ratio of 22.83 indicates that the stock may be overvalued at this price point, and the RSI of 30.09 suggests it is oversold, which could lead to a rebound. The main risk is the recent decline in revenue growth, with Q2 revenue at $18.66 million, which is lower than expected, impacting investor sentiment.

1 analysts cover PDEX: 1 rate it Buy, 0 Hold and 0 Sell.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started